These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17932809)

  • 61. Cloning of the genome of equine herpesvirus 4 strain TH20p as an infectious bacterial artificial chromosome.
    Azab W; Kato K; Arii J; Tsujimura K; Yamane D; Tohya Y; Matsumura T; Akashi H
    Arch Virol; 2009; 154(5):833-42. PubMed ID: 19387789
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunomodulatory Arming Factors-The Current Paradigm for Oncolytic Vectors Relies on Immune Stimulating Molecules.
    Peters CWD; Nigim F
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445759
    [TBL] [Abstract][Full Text] [Related]  

  • 63. HSV amplicon vectors for cancer therapy.
    Shah K; Breakefield XO
    Curr Gene Ther; 2006 Jun; 6(3):361-70. PubMed ID: 16787187
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Construction of a bacterial artificial chromosome library.
    Choi S; Kim UJ
    Methods Mol Biol; 2001; 175():57-68. PubMed ID: 11462856
    [No Abstract]   [Full Text] [Related]  

  • 65. Generation of transgenic medaka using modified bacterial artificial chromosome.
    Nakamura S; Saito D; Tanaka M
    Dev Growth Differ; 2008 Aug; 50(6):415-9. PubMed ID: 18422685
    [TBL] [Abstract][Full Text] [Related]  

  • 66. BAC to immunology--bacterial artificial chromosome-mediated transgenesis for targeting of immune cells.
    Sparwasser T; Eberl G
    Immunology; 2007 Jul; 121(3):308-13. PubMed ID: 17437533
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.
    Grant KG; Krisky DM; Ataai MM; Glorioso JC
    Biotechnol Bioeng; 2009 Mar; 102(4):1087-97. PubMed ID: 18828174
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.
    Sampath P; Thorne SH
    Oncolytic Virother; 2014; 3():1-9. PubMed ID: 27512659
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Oncolytic virotherapy with SOCS3 enhances viral replicative potency and oncolysis for gastric cancer.
    Matsumura S; Nakamori M; Tsuji T; Kato T; Nakamura M; Ojima T; Fukuhara H; Ino Y; Todo T; Yamaue H
    Oncotarget; 2021 Feb; 12(4):344-354. PubMed ID: 33659045
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Construction of an IL12 and CXCL11 armed oncolytic herpes simplex virus using the CRISPR/Cas9 system for colon cancer treatment.
    Zhang N; Li J; Yu J; Wan Y; Zhang C; Zhang H; Cao Y
    Virus Res; 2023 Jan; 323():198979. PubMed ID: 36283533
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Human artificial chromosomes: potential applications and clinical considerations.
    Basu J; Willard HF
    Pediatr Clin North Am; 2006 Oct; 53(5):843-53, viii. PubMed ID: 17027613
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Novel tracing paradigms--genetically engineered herpesviruses as tools for mapping functional circuits within the CNS: present status and future prospects.
    Boldogköi Z; Sík A; Dénes A; Reichart A; Toldi J; Gerendai I; Kovács KJ; Palkovits M
    Prog Neurobiol; 2004 Apr; 72(6):417-45. PubMed ID: 15177785
    [TBL] [Abstract][Full Text] [Related]  

  • 73. ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.
    Carson J; Haddad D; Bressman M; Fong Y
    Drugs Future; 2010; 35(3):183-195. PubMed ID: 22287818
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bacterial artificial chromosomes improve recombinant protein production in mammalian cells.
    Blaas L; Musteanu M; Eferl R; Bauer A; Casanova E
    BMC Biotechnol; 2009 Jan; 9():3. PubMed ID: 19144171
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rescue, Purification, and Characterization of a Recombinant HSV Expressing a Transgenic Protein.
    Vannini A; Petrovic B; Gatta V; Leoni V; Pepe S; Menotti L; Campadelli-Fiume G; Gianni T
    Methods Mol Biol; 2020; 2060():153-168. PubMed ID: 31617177
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Deal watch: Amgen buys oncolytic virus company.
    Nat Rev Drug Discov; 2011 Mar; 10(3):166. PubMed ID: 21358726
    [No Abstract]   [Full Text] [Related]  

  • 77. Arming Technology in Yeast-Novel Strategy for Whole-cell Biocatalyst and Protein Engineering.
    Kuroda K; Ueda M
    Biomolecules; 2013 Sep; 3(3):632-50. PubMed ID: 24970185
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Chromosome-based vectors for Mammalian cells: an overview.
    Lim HN; Farr CJ
    Methods Mol Biol; 2004; 240():167-86. PubMed ID: 14970410
    [No Abstract]   [Full Text] [Related]  

  • 79. A novel oncolytic HSV co-expressing IL-12 and anti-PD-1 for glioblastoma.
    Ayele K; Feng X; Saha D
    Mol Ther Oncol; 2024 Jun; 32(2):200810. PubMed ID: 38784951
    [No Abstract]   [Full Text] [Related]  

  • 80. Correction: Bortezomib Treatment Sensitizes Oncolytic HSV-1-Treated Tumors to NK Cell Immunotherapy.
    Clin Cancer Res; 2017 Mar; 23(5):1359-1360. PubMed ID: 28249932
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.